Isofol Medical: AGENT did not reach ORR and PFS endpoints with statistical significance
Research Note
2022-08-04
11:09
Redeye is disappointed by Isofol’s phase III AGENT trial failing to meet its primary ORR and key secondary PFS endpoints with statistical significance. We judge this presents one of the worst possible outcomes, and any path forward is highly uncertain now. We lower our valuation accordingly.
CB
Christian Binder
Disclosures and disclaimers